KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization Amortization Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Repurchased Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Non-Current Receivables Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In Process Receivables - Net Receivables - Other Receivables Refunds Shares Outstanding Shares Outstanding Shares Repurchased Short-Term Debt repayments

Novartis Ag (NVS) Short-Term Debt repayments (2019 - 2026)

Novartis Ag's Short-Term Debt repayments history spans 8 years, with the latest figure at -$73.0 million for Q1 2026.

On a quarterly basis, Short-Term Debt repayments fell 5.8% to -$73.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$285.0 million, a 7.95% decrease, with the full-year FY2025 number at -$281.0 million, down 7.25% from a year prior.
Short-Term Debt repayments hit -$73.0 million in Q1 2026 for Novartis Ag, roughly flat from -$73.0 million in the prior quarter.
Over the last five years, Short-Term Debt repayments for NVS hit a ceiling of -$59.0 million in Q2 2024 and a floor of -$77.0 million in Q1 2022.
Historically, Short-Term Debt repayments has averaged -$67.8 million across 5 years, with a median of -$66.0 million in 2023.
Biggest five-year swings in Short-Term Debt repayments: grew 20.0% in 2022 and later dropped 14.06% in 2025.
Tracing NVS's Short-Term Debt repayments over 5 years: stood at -$64.0 million in 2022, then changed by 0.0% to -$64.0 million in 2023, then fell by 12.5% to -$72.0 million in 2024, then fell by 1.39% to -$73.0 million in 2025, then changed by 0.0% to -$73.0 million in 2026.
Business Quant data shows Short-Term Debt repayments for NVS at -$73.0 million in Q1 2026, -$73.0 million in Q4 2025, and -$73.0 million in Q3 2025.